Literature DB >> 2373634

[Distal Y-gastrectomy in complex and recurrent reflux].

M Rossetti1, P Hitz, R von Aarburg.   

Abstract

The consequences of mixed esophagitis due to acid-peptic as well as biliary-pancreatic reflux are widely known today, even though they are partly accompanied by physiopathologic speculations. Much seems to indicate that the biliary component causes most pathologic modifications in the esophagus as the peptic reflux alone, such as Barrett, secondary brachyesophagus, strictures and even malignancy. In advanced cases with functional failure of the upper and lower sphincter, as well as the development of serious perifocal fibrosis in the thoraco-abdominal region or, often, in the cases with a multifactorial pathology after anti-reflux surgery, standard operations of the cardia is no longer possible. For many years resections or interpositions were proposed despite their morbidity, lethality and quality of life. The distal gastrectomy in healthy tissue with a long-Roux-Y drainage has proved to be a successful procedure. We present a study of 43 cases with an interesting pathology, as well as indications and long-term results.

Entities:  

Mesh:

Year:  1990        PMID: 2373634

Source DB:  PubMed          Journal:  Helv Chir Acta        ISSN: 0018-0181


  3 in total

1.  Early and late results of the acid suppression and duodenal diversion operation in patients with barrett's esophagus: analysis of 210 cases.

Authors:  Attila Csendes; Patricio Burdiles; Italo Braghetto; Owen Korn; Juan Carlos Díaz; Jorge Rojas
Journal:  World J Surg       Date:  2002-03-01       Impact factor: 3.352

2.  Refundoplication for recurrent gastroesophageal reflux.

Authors:  M E Luostarinen; J O Isolauri; M O Koskinen; J O Laitinen; M J Matikainen; T S Lindholm
Journal:  World J Surg       Date:  1993 Sep-Oct       Impact factor: 3.352

3.  Vagotomy, antrectomy, and Roux-en-Y diversion for complex reoperative gastroesophageal reflux disease.

Authors:  F H Ellis; S P Gibb
Journal:  Ann Surg       Date:  1994-10       Impact factor: 12.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.